FDA, Congrès, CBD… Que se passe-t-il aux États-Unis ?

FDA, Congress, CBD… What’s happening in the United States?

Since the Farm Bill was passed in 2018, legalising the production and sale of hemp and hemp-derived products containing cannabidiol (CBD) in the United States, the CBD market has grown rapidly and significantly. However, with no clear regulations from the Food and Drug Administration (FDA), consumers and businesses have had to navigate an uncertain and constantly changing legal landscape. In response, the US Congress has urged the FDA to establish rules governing the production and sale of CBD products to protect consumers’ health and safety while promoting innovation and economic growth.


However, regulating CBD has proved complex and difficult due to the wide variety of products available, the diversity of production practices and the need to protect consumers from fraudulent or dangerous products. In this context, the FDA has faced numerous challenges in regulating the CBD market effectively while balancing the needs of consumers and businesses with those of public health.


The FDA faces pressure from Congress to regulate the CBD market

Since CBD was legalised in 2018, the US Congress has encouraged the FDA to draw up rules to regulate the emerging CBD market. CBD products such as oils, capsules and cosmetics have become increasingly popular with consumers, but the lack of clear regulations has created uncertainty about their safety and efficacy. In response, legislators have pressured the FDA to regulate the CBD market quickly and establish quality and safety standards for products.
 

The challenges of regulating CBD for the FDA

However, regulating CBD has proved complex for the FDA because of the variety of products available and the diversity of production practices. Consumers have reported problems such as contaminants, excessively high THC levels, false health and safety claims, and misleading labels. The FDA has also had to contend with complex legal challenges relating to the classification of CBD and its derivatives.


The FDA’s initiatives to regulate the CBD market

To address these challenges, the FDA has launched a series of initiatives to regulate the CBD market. It has held public hearings, invited comments and published updates on its regulatory efforts. The FDA has also stepped up its efforts to crack down on illegal and misleading practices in the CBD market, such as unsubstantiated health and safety claims.


The future of CBD regulation

Despite these efforts, legislators and stakeholders in the CBD industry continue to press the FDA to publish clear regulations for the CBD market. The future of CBD regulation remains uncertain, but the FDA continues to develop rules to ensure consumer safety and support innovation and economic growth in the CBD industry.


Recent legislative developments concerning CBD in the United States

Since legalisation in 2018, the United States has seen several significant legislative developments concerning CBD. The Farm Bill allowed the production and sale of hemp and hemp-derived products containing CBD, but left questions unanswered about the regulation and classification of CBD. Since then, a series of legislative developments in the United States have affected the CBD industry and consumers.


In December 2020, Congress passed a federal spending bill that included provisions for regulating CBD products. The bill required the FDA to publish a report on CBD regulation, including quality and safety standards, within 60 days of its passage. Although the FDA published the report in March 2021, it did not provide definitive rules for regulating CBD.


In November 2021, the House of Representatives passed the CBD regulation bill, which aims to regulate the production, sale and labelling of CBD products. The bill would establish quality standards for CBD products, including limits on THC levels, and clarify the legal classification of CBD. However, the bill still needs to be passed by the Senate and signed by the President to become law.
 

These recent legislative developments concerning CBD in the United States highlight the importance of regulating the CBD market to protect consumers and support the industry’s economic growth. As CBD regulation in the United States continues to evolve, consumers and businesses need to follow the latest developments to stay informed about quality and safety standards.

The challenges of regulating CBD for the FDA: balancing safety, efficacy and legality

Regulating CBD is a major challenge for the FDA, the agency responsible for regulating food and medicines in the United States. With limited research and information available on CBD, the FDA must balance several key factors, including safety, efficacy and legality.

Safety concerns

One of the FDA’s main concerns regarding CBD regulation is safety. In the absence of sufficient research, the FDA faces challenges in assessing the safety of CBD. It is essential for the FDA to establish quality and safety standards for CBD, including maximum THC limits, to protect consumers.
 

Efficacy

The FDA must also consider the efficacy of CBD. Although some research has shown potential benefits of CBD, the FDA needs to establish standards to ensure that CBD products meet high efficacy standards.

Legality

Finally, CBD regulation must comply with federal and state laws. The FDA must work with other government agencies to clarify the legal classification of CBD and ensure that CBD products comply with all applicable laws.


These challenges are compounded by the complex nature of CBD. CBD is found in a variety of products, including foods, supplements and medicines, making it even more difficult for the FDA to regulate. However, regulation is essential to protect consumers and encourage growth in the CBD industry. The FDA must work diligently to overcome these challenges and establish clear, consistent standards for CBD regulation.

The economic stakes of the booming CBD market in the United States

The CBD market in the United States is booming, presenting significant economic opportunities and challenges. CBD is increasingly popular as a wellness, health and beauty product, with a large number of new CBD products being launched regularly.


The CBD market has become a fast-growing industry, creating new jobs and generating significant revenue. According to estimates, the CBD market in the United States is expected to reach 16 billion dollars by 2025.
 

However, this lucrative market also presents challenges for businesses and consumers. Businesses must ensure that their CBD products comply with FDA safety and quality regulations, which can be difficult given the lack of clarity in current regulations. Consumers should also exercise caution when buying CBD products, as some may contain varying amounts of CBD or other substances that could be potentially harmful.


The CBD market also faces competition from the pharmaceutical industry. Pharmaceutical companies have begun exploring the potential benefits of CBD for treating certain conditions, and some CBD products could be classified as medicines by the FDA. This could affect the regulation and availability of CBD products.


The US CBD market is therefore booming and has significant economic implications. However, it is important to strike a balance between the regulation needed to protect consumers and support industry growth, while ensuring the safety and efficacy of CBD products.

The future of CBD in the United States: how will the FDA and Congress shape the industry?

Recently, the FDA rejected three petitions asking the agency to issue regulations allowing cannabidiol (CBD) products to be marketed as food supplements, and announced that a legislative solution was needed to allow wider access to CBD products. While some may have hoped for a more direct route under the current authorities, the agency's statement nonetheless indicates a willingness to work towards a solution that meets growing demand for these products.


The future of the CBD industry in the United States will largely depend on how the FDA and Congress regulate the market. As CBD grows in popularity, it is clear that the CBD industry will continue to expand in the years ahead. However, considerable uncertainty remains about the future regulation of this booming market.


The FDA has already begun regulating some CBD products, particularly those claiming to offer medical benefits. However, CBD products intended for non-medical uses, such as food and drink, are currently in a regulatory grey area. The FDA still needs to determine how to regulate these products while ensuring their safety and efficacy.

However, after 4 years of exploring ways to regulate CBD, the FDA has just announced that it will not regulate CBD foods and food supplements. It is leaving the matter to Congress.
 

Congress also has a role to play in the future regulation of the CBD industry. Several bills have been proposed to regulate the CBD market at federal level, but none has yet been passed. The proposed bills aim to clarify federal CBD regulations, define restrictions on advertising and labelling, and clarify the distinction between CBD and THC.


The future of the CBD industry will therefore largely depend on how the FDA and Congress decide to regulate the market. If regulation is too restrictive, it could hinder industry growth. Conversely, regulation that is too lax could compromise the safety and efficacy of CBD products.


Overall, it is clear that CBD is here to stay and that the industry will continue to grow. However, the regulatory framework in which the industry will develop remains to be determined, and it is important for the FDA and Congress to work together to ensure the safety, efficacy and transparency of CBD products for consumers.